- Home
- DRUG vs MGNX Comparison
DRUG vs MGNX Comparison
Compare DRUG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- MGNX
- Stock Information
- Founded
- DRUG 2019
- MGNX 2000
- Country
- DRUG United States
- MGNX United States
- Employees
- DRUG N/A
- MGNX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- MGNX Health Care
- Exchange
- DRUG Nasdaq
- MGNX Nasdaq
- Market Cap
- DRUG 260.6M
- MGNX 257.3M
- IPO Year
- DRUG N/A
- MGNX 2013
- Fundamental
- Price
- DRUG $39.85
- MGNX $3.46
- Analyst Decision
- DRUG Buy
- MGNX Hold
- Analyst Count
- DRUG 1
- MGNX 10
- Target Price
- DRUG $75.00
- MGNX $7.17
- AVG Volume (30 Days)
- DRUG 89.2K
- MGNX 457.5K
- Earning Date
- DRUG 02-11-2025
- MGNX 11-05-2024
- Dividend Yield
- DRUG N/A
- MGNX N/A
- EPS Growth
- DRUG N/A
- MGNX N/A
- EPS
- DRUG N/A
- MGNX N/A
- Revenue
- DRUG N/A
- MGNX $141,329,000.00
- Revenue This Year
- DRUG N/A
- MGNX $174.73
- Revenue Next Year
- DRUG N/A
- MGNX N/A
- P/E Ratio
- DRUG N/A
- MGNX N/A
- Revenue Growth
- DRUG N/A
- MGNX 16.68
- 52 Week Low
- DRUG $0.93
- MGNX $2.95
- 52 Week High
- DRUG $79.02
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- DRUG 51.96
- MGNX 54.88
- Support Level
- DRUG $34.29
- MGNX $3.08
- Resistance Level
- DRUG $42.47
- MGNX $3.30
- Average True Range (ATR)
- DRUG 3.54
- MGNX 0.18
- MACD
- DRUG -0.04
- MGNX 0.03
- Stochastic Oscillator
- DRUG 61.03
- MGNX 92.63
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).